FitzGerald, J. Mark
O’Byrne, Paul M.
Bateman, Eric D.
Barnes, Peter J.
Zheng, Jinping
Ivanov, Stefan
Lamarca, Rosa
Larsdotter, Ulrika
Emerath, Ulrika
Jansen, Gerreke
Puu, Margareta
Alagappan, Vijay K. T.
Surmont, Filip
Reddel, Helen K.
Funding for this research was provided by:
AstraZeneca
Article History
Accepted: 27 December 2020
First Online: 6 February 2021
Declarations
:
: This analysis was funded by AstraZeneca.
: Paul M. O’Byrne received grants and personal fees from AstraZeneca during the conduct of the study; grants and personal fees from GlaxoSmithKline; personal fees from Menarini; and grants from MedImmune, AllerGen NCE, Genentech, Novartis, Merck, and Bayer outside of the submitted work. J. Mark FitzGerald received grants and personal fees from AstraZeneca during the conduct of the study; grants paid to his institution from the Canadian Institute for Health Research, the National Institutes for Health, AllerGen NCE, AstraZeneca, Novartis, Boehringer Ingelheim, GlaxoSmithKline, and Sanofi-Aventis outside the submitted work; and personal fees from GlaxoSmithKline, Novartis, Sanofi Regeneron, and Boehringer Ingelheim; and is a Member of the Global Initiative for Asthma (GINA) Science Committee and the GINA Board. Eric D. Bateman has received personal fees from AstraZeneca, ALK, Boehringer Ingelheim, Menarini, Novartis, Orion, Regeneron, and Sanofi-Genzyme and is a member of the GINA Science Committee and the GINA Board. Peter J. Barnes received grants and personal fees from AstraZeneca during the conduct of the study. Jinping Zheng has received personal fees from AstraZeneca. Stefan Ivanov, Rosa Lamarca, Ulrika Larsdotter, Ulrika Emerath, Gerreke Jansen, Margareta Puu, Vijay Alagappan, and Filip Surmont are all employees of AstraZeneca. Helen K. Reddel received personal fees and non-financial support from AstraZeneca during the conduct of the study; grants, personal fees, and non-financial support from AstraZeneca and GlaxoSmithKline; grants and personal fees from Novartis; and personal fees from Sanofi-Genzyme, Merck, Boehringer Ingelheim, Mundipharma, Chiesi, and TEVA outside of the submitted work; and is chair of the GINA Scientific Committee and a member of the GINA board.
: The SYGMA studies were performed in accordance with the Declaration of Helsinki and Good Clinical Practice. All patients provided written informed consent before participating in the study. The final clinical study protocols, final informed consent forms, and other written information or materials provided to patients were approved by an independent ethics committee.
: Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca’s data sharing policy described at ExternalRef removed.
: All authors reviewed and edited the manuscript and approved the final version. In addition, J Mark FitzGerald, Paul O’Byrne, Eric Bateman, Peter Barnes, and Helen Reddel contributed to the study concept and design as part of the SYGMA steering committee, and data interpretation. Jinping Zheng, Margareta Puu, Vijay Alagappan, and Filip Surmont contributed to data interpretation. Rosa Lamarca contributed to data preparation, analysis, and interpretation. Stefan Ivanov contributed to study concept and design, and data preparation and interpretation. Ulrika Emerath contributed to study concept and design, and data preparation, analysis and interpretation. Ulrika Larsdotter and Gerreke Jansen contributed to data preparation and analysis and interpretation.
: Not applicable.
: Not applicable.